Table 2.
Virologic Response in Patients With Genotype 3 Hepatitis C Virus Who Completed Therapy With Sofosbuvir and Ribavirin With or Without Peginterferon
| Treatment Regimen | SOF/Peg-IFN/RBV (n = 19) |
SOF/RBV (n = 178) |
Total (N = 197) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall SVR12 (EP) | 16/19 (84.2%) |
107/178 (60.1%) |
123/197 (62.4%) | ||||||
| PP SVR12 | 16/18 (88.9%) |
104/156 (66.7%) |
120/174 (69.0%) | ||||||
| Noncirrhotic |
Cirrhotic |
Noncirrhotic |
Cirrhotic |
||||||
| Overall SVR12 (EP) | 87.5% (7/8) |
81.8% (9/11) |
78.1% (64/82) |
44.8% (43/96) |
|||||
| PP SVR12 | 87.5% (7/8) |
90% (9/10) |
88.7% (63/71) |
48.2% (41/85) |
|||||
| TN | TE | TN | TE | TN | TE | TN | TE | ||
| SVR12 (EP) | 100% (4/4) | 75% (3/4) | 66.7% (2/3) | 87.5% (7/8) | 75.0% (42/56) | 84.6% (22/26) | 55.3% (21/38) | 37.9% (22/58) | |
| SVR12 (PP) | 100% (4/4) | 75% (3/4) | 100% (2/2) | 87.5% (7/8) | 89.1% (41/46) | 88.0% (22/25) | 57.6% (19/33) | 42.3% (22/52) | |
| Virologic failure (EP) | |||||||||
| Breakthrough | … | … | … | … | 1 | 1 | 2 | 2 | 6 |
| Relapse | … | 1 | … | 1 | 7 | 3 | 12 | 28 | 52 |
| Nonresponse | … | … | 1 | … | … | … | … | 1 | 2 |
| Non–virologic failure | … | … | … | … | 6 | … | 3 | 5 | 14 |
Abbreviations: EP, evaluable population; peg-IFN, pegylated interferon; PP, per protocol; RBV, ribavirin; SOF sofosbuvir; SVR12, sustained virologic response at 12 weeks; TE, treatment experienced; TN, treatment naive.